Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from IMGN

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

Investors Business Daily

Biotech Leader ImmunoGen Eyes Early Buy Point Amid Path To Profitability

Biotech Leader ImmunoGen Eyes Early Buy Point Amid Path To Profitability

Among the best stocks to buy and watch, ovarian cancer treatment leader ImmunoGen is approaching an early buy point in today's stock market.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips

ImmunoGen and Day One unveiled promising cancer treatment updates over the weekend, leading IMGN stock and DAWN stock to soar Monday.

Investors Business Daily

Immunogen's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million.

What's Going On With ImmunoGen Shares Today?

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.

Immunogen: Q1 Earnings Insights

Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

Immunogen Earnings Preview

Immunogen Earnings Preview

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-0.21.

Earnings Outlook For Immunogen

Earnings Outlook For Immunogen

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-1.71.

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B

ImmunoGen Inc (NASDAQ: IMGN) has

1

Organisations

BristolMyers Squibb Company

Taro Pharmaceutical Industries Ltd

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play